Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sun Pharma

- PMLiVE

Boehringer’s IL-36-targeting drug tackles rare form of psoriasis

Antibody would be first-in-class

- PMLiVE

AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod

Analysts say the drug could be a best-in-class candidate in the therapy area

- PMLiVE

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

The majority of patients on Tremfya achieved at least a 90% improvement from PASI score

Bristol Myers Squibb logo

BMS psoriasis drug hits the mark in phase II

Tyrosine kinase 2 (Tyk2) inhibitors could play major role

Scratching the surface: unmet needs in psoriasis

Director Mariel Metcalfe shares some key findings from a recent Living with psoriasis study conducted in Europe, which is now available to purchase.Psoriasis is a skin condition but its impact...

Research Partnership

- PMLiVE

GSK sells eczema and psoriasis drug to Dermavant for £250m

The British group is selling off assets outside core therapy areas to boost R&D

- PMLiVE

UK, Germany back routine use of J&J’s Tremfya

The IL-23 inhibitor is currently being assessed in other EU countries

- PMLiVE

Sun Pharma passes milestone with novel psoriasis drug approval

Ilumya will treat adults with a moderate-to-severe form of the skin condition

Research Partnership has published a new patient Living with Psoriasis (EU) report

Living with Psoriasis is a report based on a new study conducted in the main 5EU markets and Belgium and the Netherlands (reports can be purchased for either 5EU or 7EU)....

Research Partnership

Research Partnership launches new patient Living with Psoriasis 2017 (EU) report

Living with Psoriasis is a study conducted amongst 615 patients in Europe. The report will consist of 30-minute online interviews with 600 patients and 15 qualitative interviews. It can be purchased...

Research Partnership

- PMLiVE

AbbVie risankizumab trials set up psoriasis filing – and a market battle

Competes against blockbusters Stelara and Humira

- PMLiVE

European Commission backs LEO Pharma’s Kyntheum

Drug has been approved to treat moderate-to-severe plaque psoriasis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links